In 2019, Quizartinib was approved as an FLT3 inhibitor in Japan for the treatment of FLT3–ITD mutated R/R AML, and recently, on 20 July 2023, the FDA approved combination of quizartinib with a “7+3” standard chemotherapy [84]. Here, FLT3 is linked to acute myeloid leukemia.